Browse by author
Lookup NU author(s): Laura Devlin, Dr Praveen Dhondurao Sudhindar, Professor John SayerORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: Renal ciliopathies represent a collection of genetic disorders characterized by deficiencies in the biogenesis, maintenance, or functioning of the ciliary complex. These disorders, which encompass autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and nephronophthisis (NPHP), typically result in cystic kidney disease, renal fibrosis, and a gradual deterioration of kidney function, culminating in kidney failure. Areas covered: Here we review the advances in basic science and clinical research into renal ciliopathies which have yielded promising small compounds and drug targets, within both preclinical studies and clinical trials. Expert opinion: Tolvaptan is currently the sole approved treatment option available for ADPKD patients, while no approved treatment alternatives exist for ARPKD or NPHP patients. Clinical trials are presently underway to evaluate additional medications in ADPKD and ARPKD patients. Based on preclinical models, other potential therapeutic targets for ADPKD, ARPKD, and NPHP look promising. These include molecules targeting fluid transport, cellular metabolism, ciliary signaling and cell-cycle regulation. There is a real and urgent clinical need for translational research to bring novel treatments to clinical use for all forms of renal ciliopathies to reduce kidney disease progression and prevent kidney failure.
Author(s): Devlin L, Dhondurao Sudhindar P, Sayer JA
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Therapeutic Targets
Year: 2023
Volume: 27
Issue: 4-5
Pages: 325-346
Online publication date: 27/05/2023
Acceptance date: 23/05/2023
ISSN (print): 1472-8222
ISSN (electronic): 1744-7631
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/14728222.2023.2218616
DOI: 10.1080/14728222.2023.2218616
PubMed id: 37243567
